Clinical Trial Results
During recent clinical trials that paired Gilead Sciences GS-7977 with Bristol-Myers Squibb’s Daclatasvir for the treatment of Hepatitis C, 100% of genotype 1 patients and 91% of genotype 2 & 3 patients were cured. And, this was achieved without the utilization of Interferon or Ribavirin, as reflected in this snapshot of the Clinical Trial Results.
Acute hepatitis C and pertussis increasing beyond historical limits
The figure above shows selected notifiable disease reports for the United States, with comparison of provisional 4-week totals through September 15, 2012, with historical data. Reports of acute hepatitis C, legionellosis, and pertussis all increased, with acute hepatitis C and pertussis increasing beyond historical limits. Reports of giardiasis, acute hepatitis A, acute hepatitis B, measles, meningococcal disease, and mumps all decreased, with giardiasis and acute hepatitis B decreasing beyond historical limits.Link to the full CDC data